Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry
Delaney R. Kirchmeier(Fred Hutch Cancer Center), Cameron J. Turtle(The University of Sydney), Erik L. Kimble(University of Washington), Cassie Chou(University of Washington), Alexandre V. Hirayama(University of Washington), Salvatore Fiorenza, Alyssa Sheih(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alison S. Williams(Fred Hutch Cancer Center), Colin Correnti(University of Washington), Jason Price(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
|Blood|2016|743
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
|Nature Biotechnology|2017|623